Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors

The dual protein kinase-transcription factor, ERK5, is an emerging drug target in cancer and inflammation, and small-molecule ERK5 kinase inhibitors have been developed. However, selective ERK5 kinase inhibitors fail to recapitulate ERK5 genetic ablation phenotypes, suggesting kinase-independent fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Lochhead, Pamela A., Tucker, Julie A., Tatum, Natalie J., Wang, Jinhua, Oxley, David, Kidger, Andrew M., Johnson, Victoria P., Cassidy, Megan A., Gray, Nathanael S., Noble, Martin E. M., Cook, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069993/
https://www.ncbi.nlm.nih.gov/pubmed/32170057
http://dx.doi.org/10.1038/s41467-020-15031-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069993/
https://www.ncbi.nlm.nih.gov/pubmed/32170057
http://dx.doi.org/10.1038/s41467-020-15031-3

Ejemplares similares